MetaCap

Immatics N.V. (IMTX) vs Inhibrx Biosciences (INBX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inhibrx Biosciences (INBX) has outperformed Immatics N.V. (IMTX) over the past year, losing 17.8% versus a loss of 43.4%. Inhibrx Biosciences is the larger company by market cap ($1.02 billion vs $878.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMTX-43.43%INBX-17.82%
+75%+13%-49%
Nov 21, 20251 yearNov 20, 2026
IMTX-47.69%INBX+324.43%
+767%+329%-108%
May 27, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMTX versus INBX key metrics
MetricIMTXINBX
Share price$5.77$68.97
Market cap$878.58M$1.02B
1-day change-3.03%-7.21%
YTD return-45.05%-12.70%
1-year return-43.43%-17.82%
5-year return-48.57%—
EPS (TTM)$-1.95$-9.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.30M
Revenue growth (YoY)—+550.00%
Net income (latest FY)—$-140.06M
Operating margin—-10386.54%
Net margin—-10773.46%
52-week high$12.41$155.29
52-week low$5.72$57.30
Distance from 52-week high-53.51%-55.59%
Analyst consensusstrong_buynone
Avg. price target upside+176.78%+286.65%
Average volume962.74K305.96K
Shares outstanding152.27M14.77M
Employees721109
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INBX has outperformed IMTX by 25.6 percentage points over the past year.

About Immatics N.V.

IMTX stock →

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees

About Inhibrx Biosciences

INBX stock →

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

IMTX vs INBX FAQ

Which is bigger, Immatics N.V. or Inhibrx Biosciences?

Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.02B compared with $878.58M for Immatics N.V. (IMTX).

Which stock has performed better over the past year, IMTX or INBX?

INBX returned -17.82% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.

Are Immatics N.V. and Inhibrx Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons